Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

Lenalidomide has been linked to second primary malignancies in myeloma. We aimed to pool and analyse available data to compare the incidence of second primary malignancies in patients with and without lenalidomide exposure. We identified relevant studies through a search of PubMed and abstracts from...

Celý popis

Podrobná bibliografie

Vydáno v:	The lancet oncology Ročník 15; číslo 3; s. 333 - 342
Hlavní autoři:	Palumbo, Antonio, Bringhen, Sara, Kumar, Shaji K, Lupparelli, Giulia, Usmani, Saad, Waage, Anders, Larocca, Alessandra, van der Holt, Bronno, Musto, Pellegrino, Offidani, Massimo, Petrucci, Maria T, Evangelista, Andrea, Zweegman, Sonja, Nooka, Ajay K, Spencer, Andrew, Dimopoulos, Meletios A, Hajek, Roman, Cavo, Michele, Richardson, Paul, Lonial, Sagar, Ciccone, Giovannino, Boccadoro, Mario, Anderson, Kenneth, Barlogie, Bart, Sonneveld, Pieter, McCarthy, Philip L
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Ltd 01.03.2014 Elsevier Limited
Témata:	Age Angiogenesis Inhibitors - adverse effects Bone marrow Hematology Hematology, Oncology and Palliative Medicine Humans Melphalan - adverse effects Meta-analysis Multiple Myeloma - drug therapy Multivariate analysis Neoplasms, Second Primary - chemically induced Patients Thalidomide - adverse effects Thalidomide - analogs & derivatives Transplants & implants
ISSN:	1470-2045, 1474-5488, 1474-5488
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!